Abstracts

INTACT HIV GENOMES ARE ENRICHED IN MEMORY T CELLS WITH SHORT HALF-LIVES

Future HIV curative therapies require a thorough understanding of the distribution of genetically intact HIV within T cell subsets during short-term antiretroviral therapy (ART) and the cellular mechanisms which maintain this reservoir. Therefore, we genetically characterized HIV genomes within T cell subsets from participants on <4 years of therapy. Seven participants were treated for <4…

LONGITUDINAL CHARACTERIZATION OF HIV PROVIRUSES IN PEOPLE ON SUPPRESSIVE ART

Clonal proliferation of CD4+ T cells harboring HIV proviruses is a major contributor to HIV persistence despite antiretroviral therapy (ART). Most proviruses are defective, and it is unknown whether cells harboring intact and defective proviruses or those with escape epitopes experience differential rates of clonal expansion and persistence during ART. To determine whether HIV-specific cytotoxic…

HIGH-THROUGHPUT SEQUENCING OF INTEGRATED HIV-1 REVEALS NOVEL PROVIRAL STRUCTURES

Efforts to cure HIV-1 infection will require a better understanding of the HIV-1 reservoir but characterizing individual integrated proviruses has remained difficult because of technical challenges related to the rarity of proviruses in CD4+ T-cells. Current approaches for sequencing integration sites using NGS are inefficient (most reads are off-target reads) and restricted read lengths can…

HIV DYNAMICS AND REPOPULATION OF RESERVOIRS IN THE HUMAN BODY

Characterizing HIV persistence and dynamics across the human body is important to develop ways to clear reservoirs. This goal has been hampered by technical difficulties and obtaining fresh tissues. Samples were obtained from 6 Last Gift participants, who provided blood ante-mortem and their whole bodies for rapid autopsy within 6 hours of death. Two voluntarily…

AMINOBISPHOSPHONATES REVERSE LATENCY IN HIV-SEROPOSITIVE INDIVIDUALS

We hypothesized that aminobisphosphonates (N-BPs), such as pamidronate (PAM), zoledronate (Zol) and alendronate (ALN), that inhibit the formation of farnesyl pyrophosphate groups, used for protein prenylation disrupting cell signaling, may induce reversal of HIV latency. Therefore, here we explore their potential as novel latency reversing agents. Latency reactivation capacity of N-BPs was analyzed ex vivo…

SURFACE ENGINEERING OF EXTRACELLULAR VESICLES TO TARGET HIV PERSISTENCE

Current limitations of antiretroviral therapy are driving interest in novel HIV eradication strategies. Extracellular vesicles (EVs) are nano-sized membrane vesicles involved in cell signaling which have shown promise as engineerable therapeutic agents. We used surface display technology to engineer HIV-targeting EVs (HTEVs) that block HIV infection and target infected cells. EVs were isolated from healthy donor…